Although the article1 demonstrates a dose-dependent gradient in response, the precise dose dependency of effect for any particular outcome or any particular pleiotropic mechanism cannot be fully ascertained from this study. If such therapy was to be implemented, it is unclear how to determine a protective dose in the setting of an influenza pandemic or for more general use in COPD patients. The results suggest, however, that titration to maximally tolerated doses might be a reasonable, initial approach pending further studies, especially randomized trials. The diversity of the databases mandated a focus on in-hospital deaths only. While this pragmatic approach yields a clear-cut and compelling end point, particularly with respect to acute influenza-related deaths that are often in the hospital, the analysis does not provide an assessment of the potential, overall impact of statin therapy in COPD that has a more protracted course, characterized by a high degree of both outpatient and inpatient morbidity and mortality. It is not clear whether this limitation of the study might have resulted in an overestimation or underestimation of putative effects of stains in COPD. Indeed, the beneficial effects on mortality must be viewed as speculative due to inevitably imperfect elimination of all variables that might potentially confound the final results and the potential for ascertainment and treatment biases. Thus, in spite of the novel and interesting results, the evidence provided by this sort of retrospective analysis is valuable mainly for providing a compelling rationale for executing randomized clinical trials that will more clearly define the magnitude of effect and the characteristics of patients that will benefit the most. Even so, the current article is extremely valuable because it suggests that statin therapy may well be efficacious in real-world application to COPD patients and possibly for acute influenza. Moreover, if randomized clinical trials confirm a level of efficacy similar to what was noted in this trial (risk reductions in the 40 to 80% range), then such therapy may also be extremely efficient or cost-effective.